Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14)
Lancet Gastroenterol Hepatol. 2022 Oct 31;S2468-1253(22)00335-1. Online ahead of print.
DOI: 10.1016/S2468-1253(22)00335-1
Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22
Transl Lung Cancer Res. 2022 Jul;11(7):1369-1379
DOI: 10.21037/tlcr-22-79
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial
JAMA Oncol. 2022 Sep 1;8(9):1271-1277.
DOI: 10.1001/jamaoncol.2022.2310.
A Phase II Study of Nivolumab Plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11)
Clin Cancer Res. 2022 Oct 3;28(19):4240-4247.
Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07
J Clin Oncol. 2022 Nov 20;40(33):3868-3877. Epub 2022 Jun 30.
Discussing POLST-facilitated hospice care enrollment in patients with terminal cancer
Support Care Cancer. 2022 Sep;30(9):7431-7438. Epub 2022 May 27.
A Phase II Study of Nivolumab Plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11)
Clin Cancer Res. 2022 Oct 3;28(19):4240-4247.
Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09)
Cancer Res Treat. 2022 Mar 24. Online ahead of print.
Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11)
Cancer. 2022 Feb 15;128(4):778-787. Epub 2021 Oct 27.
Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01)
Korean J Intern Med. 2022 Jan;37(1):190-200. Epub 2021 Dec 21.
Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16)
Gastric Cancer. 2022 May;25(3):609-618. Epub 2022 Jan 11.
Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group
Cancer Res Treat. 2022 Jan;54(1):1-9. Epub 2021 Dec 13.
